AVALO THERAPEUTICS, INC. Increase (Decrease) in Restricted Cash for Operating Activities
AVALO THERAPEUTICS, INC. (AVTX) reported Increase (Decrease) in Restricted Cash for Operating Activities of $59.37 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-04-02.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities · last filed 2018-04-02
- AVALO THERAPEUTICS, INC. increase (decrease) in restricted cash for operating activities for the quarter ending 2017-12-31 was $41.31K.
- AVALO THERAPEUTICS, INC. increase (decrease) in restricted cash for operating activities for the quarter ending 2017-09-30 was $15.87K, a 79.93% decline year-over-year.
- AVALO THERAPEUTICS, INC. increase (decrease) in restricted cash for operating activities for the quarter ending 2017-06-30 was -$6.90K.
- AVALO THERAPEUTICS, INC. increase (decrease) in restricted cash for operating activities for the quarter ending 2017-03-31 was $9.10K.
- AVALO THERAPEUTICS, INC. increase (decrease) in restricted cash for operating activities for fiscal 2017 was $59.37K, a 293.02% increase from fiscal 2016.
- AVALO THERAPEUTICS, INC. increase (decrease) in restricted cash for operating activities for fiscal 2016 was $15.11K.
- AVALO THERAPEUTICS, INC. increase (decrease) in restricted cash for operating activities for fiscal 2015 was -$116.67K, a 23526.91% decline from fiscal 2014.
- AVALO THERAPEUTICS, INC. increase (decrease) in restricted cash for operating activities for fiscal 2014 was $498.00.
| Period end | Increase (Decrease) in Restricted Cash for Operating Activities 3 month | Increase (Decrease) in Restricted Cash for Operating Activities 6 month | Increase (Decrease) in Restricted Cash for Operating Activities 9 month | Increase (Decrease) in Restricted Cash for Operating Activities 9 month as first filed | Increase (Decrease) in Restricted Cash for Operating Activities 12 month | Increase (Decrease) in Restricted Cash for Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2017-12-31 | $41.31K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $57.17K derived: sum of 2 quarters · filed 2018-04-02 | $50.27K derived: sum of 3 quarters · filed 2018-04-02 | $59.37K 10-K · filed 2018-04-02 | ||
| 2017-09-30 | $15.87K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $8.97K derived: sum of 2 quarters · filed 2017-11-07 | $18.07K 10-Q · filed 2017-11-07 | -$45.88K derived: sum of 4 quarters · filed 2018-04-02 | ||
| 2017-06-30 | -$6.90K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $2.20K 10-Q · filed 2017-08-14 | -$61.74K derived: sum of 3 quarters · filed 2018-04-02 | $17.31K derived: sum of 4 quarters · filed 2018-04-02 | ||
| 2017-03-31 | $9.10K 10-Q · filed 2017-05-09 | -$54.85K derived: sum of 2 quarters · filed 2018-04-02 | $24.20K derived: sum of 3 quarters · filed 2018-04-02 | $24.20K derived: sum of 4 quarters · filed 2018-04-02 | ||
| 2016-12-31 | -$63.94K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $15.11K derived: sum of 2 quarters · filed 2018-04-02 | $15.11K derived: sum of 3 quarters · filed 2018-04-02 | $15.11K 10-K · filed 2018-04-02 | ||
| 2016-09-30 | $79.05K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $79.05K derived: sum of 2 quarters · filed 2017-11-07 | $79.05K 10-Q · filed 2017-11-07 | -$79.05K 10-Q · filed 2016-11-08 | -$95.95K derived: sum of 4 quarters · filed 2018-04-02 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $0.00 10-Q · filed 2017-08-14 | -$175.00K derived: sum of 3 quarters · filed 2018-04-02 | |||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-09 | -$175.00K derived: sum of 2 quarters · filed 2018-04-02 | ||||
| 2015-12-31 | -$175.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | -$116.67K 10-K · filed 2018-04-02 | $116.67K 10-K · filed 2016-03-23 | |||
| 2015-09-30 | $58.33K 10-Q · filed 2016-11-08 | |||||
| 2015-03-31 | $58.33K 10-Q · filed 2016-05-16 | $59.18K derived: sum of 2 quarters · filed 2017-03-14 | ||||
| 2014-12-31 | $848.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | $498.00 10-K · filed 2017-03-14 | -$498.00 10-K · filed 2016-03-23 | |||
| 2014-09-30 | -$350.00 10-Q · filed 2015-11-13 | |||||
| 2013-12-31 | -$175.00K 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |